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Abstract
Background: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by
enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in
malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteinases. This study
determined whether doxycycline can block MMP activity in vitro. We also measured MMP-2 and MMP-9 levels in
cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas.
Methods: To determine whether doxycycline can block MMP activity, we measured the extent of doxycyline-
mediated MMP-2 and MMP-9 inhibition in vitro using epidermal growth factor receptor (EGFR) transfected U251
glioma cell lines. MMP activity was measured using sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) zymography. In addition, patients underwent lumbar puncture for CSF sampling at baseline, after 6
weeks (1 cycle), and after 12 weeks (2 cycles), while being treated with a novel chemotherapy regimen of
irinotecan, thalidomide, and doxycycline designed to block growth/proliferation, angiogenesis, and invasion.
Irinotecan was given at 125 mg/m2/week for 4 weeks in 6-week cycles, together with continuous doxycycline at
100 mg twice daily on Day 1 and 50 mg twice daily thereafter. Daily thalidomide dose in our cohort was 400 mg.
Tumor progression was monitored by magnetic resonance imaging (MRI).
Results: Doxycyline in vitro completely abolished MMP-9 activity at 500 μg/ml while there was only 30 to 50%
inhibition of MMP-2 activity. Four patients respectively completed 4, 3, 1, and 2 cycles of irinotecan, thalidomide,
and doxycycline. Patient enrollment was terminated after one patient developed radiologically defined pulmonary
embolism, and another had probable pulmonary embolism. Although CSF MMP-2 and 130 kDa MMP levels were
stable, MMP-9 level progressively increased during treatment despite stable MRI.
Conclusion: Doxycycline can block MMP-2 and MMP-9 activities from glioma cells in vitro. Increased CSF MMP-
9 activity could be a biomarker of disease activity in patients with malignant gliomas, before any changes are
detectable on MRI.
Published: 11 January 2008
Cerebrospinal Fluid Research 2008, 5:1 doi:10.1186/1743-8454-5-1
Received: 6 July 2007
Accepted: 11 January 2008
This article is available from: http://www.cerebrospinalfluidresearch.com/content/5/1/1
© 2008 Wong et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cerebrospinal Fluid Research 2008, 5:1 http://www.cerebrospinalfluidresearch.com/content/5/1/1
Page 2 of 8
(page number not for citation purposes)
Background
Matrix metalloproteinases (MMPs) are Zn2+- or Ca2+-
dependent proteinases that remodel the extracellular
matrix during development and cancer metastasis [1,2].
In malignant gliomas, MMP-2 and MMP-9 are the most
abundant forms of MMPs [3-5], while the 130 kDa MMP
may represent a complex of MMP-9 and tissue inhibitor of
matrix metalloproteinase-1, or a dimer of MMP-9 [6-8].
Both MMP-2 and MMP-9 have to be cleaved, either by an
inefficient auto-activation process or by other active pro-
teinases, in order to become activated metalloproteinases.
Their activities can be blocked by sequestration of Zn2+ or
Ca2+ [1,2]. Alternatively, tetracycline and its congeners,
including doxycycline, may inhibit MMP activities [9,10].
Malignant gliomas are characterized by three major phys-
iological processes: growth/proliferation, angiogenesis,
and invasion [11]. Traditional cytotoxic chemotherapies
control malignant gliomas by blocking growth and prolif-
eration mechanisms, but leave angiogenesis and invasion
unchecked. Furthermore, Macdonald's response criteria
[12], an established magnetic resonance imaging (MRI)
measure of cytotoxic chemotherapy efficacy, cannot ade-
quately measure antiangiogenic and anti-invasion drug
effects. For example, putative MMP inhibitors designed to
block tumor cell migration, like marimastat and prinom-
astat, have undergone phase II clinical trials for malignant
gliomas in combination with cytotoxic chemotherapies
[13,14]; but there was no radiographic response and no
prolongation of patient survival. It remains unclear
whether such disappointing results were due to insuffi-
cient inhibition of MMPs or alternative mechanisms of
tumor cell migration. Therefore, separate measures of
drug efficacy for growth/proliferation, angiogenesis, and
invasion may be necessary.
In this study we determined whether or not doxycycline
could block MMP-2 and MMP-9 activities, by measure-
ments of doxycyline-mediated MMP-2 and MMP-9 inhi-
bition  in vitro using epidermal growth factor receptor
(EGFR) transfected U251 glioma cell lines. We also incor-
porated doxycyline in a phase I clinical trial using a novel
chemotherapy regimen of irinotecan, thalidomide, and
doxycycline to treat recurrent malignant gliomas. In this
trial, we determined the cerebrospinal fluid (CSF) MMP
activities in glioma patients, in an attempt to correlate
MMPs with malignant glioma activity in vivo.
Methods
In vitro inhibitory activity of doxycycline against matrix 
metalloproteinases
In order to demonstrate the inhibitory activity of doxycy-
cline on MMPs secreted by glioma cells, U251 human gli-
oma cells stably transfected with a full-length EGFR in
pcDNA3.1neo (Invitrogen, Carlsbad, CA, USA) were
grown in Dulbecco's modified Eagle's medium (DMEM)
with 10% fetal bovine serum to mid-log phase. Cells were
then treated in serum-free DMEM for 72 hours. Ten μl of
supernatant was treated with 0, 10, 50, 100, 500, and
1,000  μg/ml of doxycycline, and the MMP gelanolytic
activities were evaluated by zymography (see CSF SDS-
PAGE Zymography). The experiments were performed in
triplicate.
Patient selection
All patients signed informed consent for participation in
this clinical trial, as well as the accompanied neuroimag-
ing and CSF analyses. They were also required to partici-
pate in FDA-mandated System for Thalidomide Education
and Prescribing Safety (S.T.E.P.) program. The procedures
for this trial were in accordance with the ethical standards
of the Committee for Clinical Investigation at Beth Israel
Deaconess Medical Center and with the Helsinki Declara-
tion of 1975, as revised in 1983.
Four patients were recruited using the following proce-
dures: Adults were identified with recurrent malignant gli-
omas, including glioblastoma multiforme, anaplastic
astrocytoma, anaplastic oligodendroglioma, mixed ana-
plastic oligoastrocytoma, and anaplastic ganglioglioma,
after initial surgery and involved-field cranial irradiation.
Additional inclusion criteria include age ≥ 18; Karnofsky
Performance Score (KPS) ≥ 60; bi-dimensionally measur-
able disease on gadolinium-enhanced head MRI; and sta-
ble corticosteroid dose for at least 3 days before
enrollment. Patients must have had adequate hematolog-
ical profiles, including absolute neutrophils ≥ 1,500/
mm3, white blood cells ≥ 3,000/mm3, and platelets ≥
100,000/mm3. Serum blood urea nitrogen, creatinine,
total bilirubin, and direct bilirubin must have been ≤ 1.5
× upper limit laboratory normal, and also ≤ 3.0 × upper
limits of laboratory normal for alanine aminotransferase
and aspartate aminotransferase and ≤ 2.0 × upper limit of
laboratory normal for liver-derived alkaline phosphatase.
Patients were excluded if they had multifocal gliomas, gli-
omatosis cerebri, low-grade gliomas, or leptomeningeal
spread of malignant gliomas. Additional exclusion criteria
included a KPS < 60; chemotherapy, immunotherapy, or
biologic therapy within 4 weeks prior to enrollment; inad-
equate recovery from prior therapies; poor medical risks;
pre-existing peripheral neuropathy; P450 hepatic enzyme-
inducing anticonvulsant intake (including phenytoin, car-
bamazepine, and phenobarbital); concurrent malignan-
cies other than surgically cured carcinoma in situ of the
cervix, and basal cell and squamous cell carcinoma of the
skin; known HIV infection or AIDS-related illnesses; preg-
nant or nursing women; and inability to undergo FDA-
mandatory S.T.E.P. program.Cerebrospinal Fluid Research 2008, 5:1 http://www.cerebrospinalfluidresearch.com/content/5/1/1
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Treatment schedule and response assessment
Patients received standard intravenous irinotecan at 125
mg/m2/week for 4 weeks in 6-week cycles [15]. On day 1
of irinotecan, they also took oral doxycycline at a dose of
100 mg twice daily, followed by 50 mg twice daily contin-
uously thereafter. Daily thalidomide at a dose of 400 mg
was also started on day 1 of irinotecan [16,17]. Patients
received irinotecan, thalidomide, and doxycycline until
disease progression or toxicity.
Tumor response was assessed by MRI every 6 weeks
according to Macdonald's criteria [12]. High-resolution
T1- and T2-weighted, gradient-echo, diffusion, arterial
spin labeling (ASL) perfusion, and post gadolinium T1-
weighted images (on axial, coronal, and sagittal axes) of
the brain were acquired on a 3.0-Tesla MRI scanner (Gen-
eral Electric Healthcare Technologies, VH/I, Waukesha,
WI, USA). A complete response was defined as resolution
of all enhancements on MRI, while a partial response was
≥ 50% reduction of the product of bi-dimensional diame-
ter of the tumor. Progressive disease was defined as ≥ 25%
increase in size of the enhancing tumor, new tumor, or
worsening neurological status requiring an increase in
dose of corticosteroid. Everything else would be classified
as stable disease. No prophylactic anticoagulation was
prescribed unless there was a documented thromboem-
bolic event.
CSF SDS-PAGE zymography
The ethics committee approved three lumbar punctures
per patient only, because these procedures were not stand-
ard of care for managing recurrent malignant gliomas. In
order to obtain the most informative data, CSF samples
were taken from patients before (baseline), after 6 weeks
(1 cycle), and after 12 weeks (2 cycles) of treatment, for
routine analysis and zymography. Samples for zymogra-
phy were stored immediately at -80°F until batch analysis.
The preparation of CSF zymography gels was previously
described [18]. Briefly, zymography gels were made from
0.1% gelatin (Sigma, St. Louis, MO, USA) loading gels
and 7.5% acrylamide (Sigma) stacking gels, and allowed
to polymerize by adding 200 μl of ammonium persulfate
(Sigma) and 50 μl of TEMED (Sigma). Twenty-five μl of
CSF was loaded into polymerized gel for electrophoresis
in a running buffer (25 mM Tris, 190 mM glycine, and 3.5
mM SDS) at 25 mA for 1 hour. After electrophoresis, gels
were transferred into 2.5% tritionX wash for 1 hour, fol-
lowed by an overnight incubation at 37°C with digestion
buffer (10 mM calcium chloride and 20 mM tris acetate at
pH of 7.5). Gels were stained for 1 hour with Coomassie
brilliant blue R-250 (Bio-Rad, Hercules, CA, USA), fol-
lowed by destaining in a solution containing 10% acetic
acid and 5% methanol for 3 hours.
The MMP-2, MMP-9, and 130 kDa gelanolytic activities
were measured by scoring the intensity of bands by com-
puterized image analysis (Odessey® Imaging System, LI-
COR Biotechnology, Lincoln, NE, USA). The CSF zymog-
raphy experiments were performed in triplicate. The mean
and standard error of the data points were plotted against
time, and analyzed using linear mixed model for signifi-
cance after log or squared transformation.
Results
Doxycycline dose response
Doxycycline was studied in vitro using EGFR-transfected
U251 glioma cells that secrete MMPs in order to evaluate
the extent of MMP blockade. At a concentration of 100 μg/
ml, doxycycline blocked > 50% MMP-9 gelanolytic activ-
ity from U251 cells overexpressing EGFR and completely
abolished it at 500 μg/ml (Figure 1A &1B). The inhibitory
activity of doxycycline for MMP-2 was less robust. There
was at least 30% inhibition starting at 10 μg/ml but no
complete block was observed at 1,000 μg/ml (Figures 1A
&1B).
Clinical trial result
Four patients completed 4, 3, 1, and 2 cycles of irinotecan,
thalidomide, and doxycycline, respectively. The histolo-
gies consisted of 1 glioblastoma multiforme, 1 anaplastic
astrocytoma, and 2 anaplastic oligodendrogliomas. All
four patients tolerated treatment without a need for dose
modification. Two patients died before tumor progres-
sion: one had CT angiogram-confirmed pulmonary
thromboembolism, and another died during sleep, prob-
ably from pulmonary thromboembolism although no
autopsy was granted. The other two did not develop
thromboembolism. Their time to tumor progression was
4 and 6 months, while the survival of the cohort was 5, 8,
10, and 17+ months (Table 1). All were able to undergo
neuroimaging evaluations and three lumbar punctures.
Tumor response and perfusion by MRI
During the initial 12-week period, no detectable tumor
progression was observed on gadolinium-enhanced T1-
weighted MRI. The perfusion results from ASL also did not
demonstrate evidence of tumor progression. Later neu-
roimaging results in Patients 1 and 2, at week 30 and 18
respectively, were consistent with tumor progression.
CSF analysis
All had negative CSF cytology for malignant cells. No acti-
vated MMP-2 (68 kDa) or activated MMP-9 (84 kDa)
bands were detected on CSF zymography. The intensity of
non-cleaved MMP-2 (72 kDa) and 130 kDa metallopro-
teinase gelanolytic bands, as measured by computerized
densitometry, was stable at baseline, after 6 weeks (1
cycle), and after 12 weeks (2 cycles) of treatment (Figures
2A and 2B). There were no significant differences overCerebrospinal Fluid Research 2008, 5:1 http://www.cerebrospinalfluidresearch.com/content/5/1/1
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time in MMP-2 and 130 kDa metalloproteinase activities.
In contrast, there was a significant increase in MMP-9 (92
kDa) levels after 6 and 12 weeks of therapy compared to
baseline (Figures 2A and 2B; p = 0.007). MMP-9 activity at
week 12 was significantly higher than activities at baseline
(p = 0.003) and at 6 weeks (p = 0.03), but there was no sig-
nificant difference in MMP-9 activities between baseline
and 6 weeks. However, when time was incorporated as a
In vitro MMP inhibitory activity of doxycycline Figure 1
In vitro MMP inhibitory activity of doxycycline. (A) Zymography gel (light-dark reversed for clarity) of the in vitro effect on 
MMP-9 and MMP-2 activities by doxycycline. In U251 glioma cells overexpressing EGFR, doxycycline blocked completely MMP-
9 gelanolytic activity at 500 μg/ml, while it only blocked partially MMP-2 activity at 1,000 μg/ml. (B) Normalized band intensity 
of gelanolytic activity of MMPs from U251 cells overexpressing EGFR at increasing concentrations of doxycyline. The IC50 was 
estimated to be 75 μg/ml for MMP-9 (red), while it was 500 μg/ml for MMP-2 (blue). Data are means +/- SEM, n = 4.Cerebrospinal Fluid Research 2008, 5:1 http://www.cerebrospinalfluidresearch.com/content/5/1/1
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continuous variable in our analysis, there was an increas-
ing trend in MMP-9 activities over time (p = 0.001).
Discussion
Doxycycline, like tetracycline and its congeners, is a water-
soluble non-specific competitive inhibitor of MMPs.
Although doxycycline may dissociate from MMPs during
SDS-PAGE, both MMP-2 and MMP-9 gelanolytic activities
decreased as shown in our in vitro assay. To explain this
phenomenon, one possibility is that doxycyline's small
molecular weight and negative charge enable it to co-
migrate with MMPs and inhibit MMP-2 and MMP-9 activ-
ities. An alternative explanation is that doxycycline has a
non-competitive inhibitory effect on MMPs. Nevertheless,
the high value of doxycycline IC50 estimated for MMP-2
and MMP-9 suggests that it blocks MMPs inefficiently.
The CSF zymography showed increasing MMP-9 gelano-
lytic activity over time. One source of this MMP-9 could
come from the choroid plexus [19], and choroid plexus
secretion may provide a basal level of MMP-9 in the CSF.
Another source of this MMP-9 may be from bone marrow-
derived hematopoietic progenitor cells helping tumor
angiogenesis [20,21]. Friedberg et al [22] noted that acti-
vated MMP-2 and MMP-9 were primarily elevated in
patients with glioblastoma multiforme and anaplastic
astrocytomas with concurrent positive CSF cytology for
malignant cells. Similarly in lymphomatous meningitis,
MMP-9, but not MMP-2 or 130 kDa MMP, correlated with
disease activity [18]. In both studies, MMP-9 activity
appears to be more sensitive than MMP-2 for malignan-
cies in the CNS, as a basal level of MMP-2 gelanolytic
activity was detected in healthy normal controls [18,22].
This is in contradiction to an immunohistochemical study
of astrocytic brain tumors by Kunishio et al [23] who
demonstrated that invasion correlated with MMP-2 but
not MMP-9. But this difference may be the result of anal-
ysis performed on CSF samples versus brain tumor speci-
mens. In our patients, no activated MMP-9 was detected
and none of our patients had positive CSF cytology for
malignant cells. Therefore, the increasing MMP-9 activity
in our cohort may reflect malignant glioma disease activ-
ity. There was also a slight decrease in the 130 kDa gelati-
nase band over time but this was not significant when
averaged among all four patients.
In our patients, it is significant to note that CSF MMP-9
activity began to rise after 6 weeks of treatment despite rel-
atively stable gadolinium enhancement and ASL per-
fusion. Changes in gadolinium enhancement and ASL
perfusion were detected much later in two patients. Per-
haps increasing MMP-9 activity portends tumor progres-
sion and it could be used as a marker to detect early tumor
progression. Additional CSF analysis beyond cycle 2
would be helpful to address this issue. Furthermore,
because angiogenesis depends on an ensemble of cellular
functions, including endothelial cell proliferation, adhe-
sion and migration in the extracellular matrix, morpho-
genesis, and MMP secretion, doxycycline may help to
potentiate the antiangiogenesis effect of thalidomide. But
the optimal dose of doxycycline to block glioma invasion
and angiogenesis remains to be determined.
In this clinical trial, patient enrollment had to be termi-
nated due to side effects. After enrolling four patients, one
developed progressive pulmonary thromboembolism
despite anticoagulation with warfarin, while another
probably died from the same adverse event during sleep.
These two adverse events could be a result of the malig-
nant gliomas since the incidence of thromboembolism is
24% in these patients [24]. Furthermore, both patients
were on concurrent dexamethasone and the risk of throm-
boembolism from taking thalidomide and dexametha-
sone was estimated to be up to 30% in patients with
multiple myeloma [25,26]. Although most reports came
from patients with multiple myeloma, thalidomide- and
dexamethasone-induced thromboembolism may not be
unique to this population as patients with mantle cell
lymphoma [27] and Waldenström's macroglobulinemia
[28] also encountered an increased rate of thromboembo-
lism. However, low molecular weight heparin may lower
this risk. When patients with multiple myeloma were
treated with thalidomide, chemotherapy, and
nadroparine, their incidence of thromboembolism
decreased to 10% [29].
Conclusion
In our cohort of four patients with recurrent malignant
gliomas, CSF MMP-9 activity progressively increased
before any evidence of tumor progression on MRI. This
finding suggests that CSF MMP-9 could be a marker for
Table 1: Treatment data on patients treated with irinotecan, thalidomide, and doxycycline
Patient Age Histology Number of Cycles TTPa OSa
1 61 anaplastic oligodendroglioma 4 6 months 17+ months
2 67 glioblastoma multiforme 3 4 months 10 months
3 54 anaplastic astrocytoma 1 N/A 5 month
4 34 anaplastic oligodendroglioma 2 N/A 8 months
aTTP = time to tumor progression; OS = overall survivalCerebrospinal Fluid Research 2008, 5:1 http://www.cerebrospinalfluidresearch.com/content/5/1/1
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early detection of tumor progression. The optimal dose of
doxycycline necessary to block all MMP activities is
unknown.
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